类风湿性关节炎动物模型制备与发病机理的探讨
|
摘要
类风湿性关节炎(rheumatoid arthritis,RA)是一种以关节滑膜炎、破坏性关节病变为主要特征的慢性、自身免疫性疾病,致畸、致残率极高。对于RA至今尚无特效疗法,东北农业大学生命科学学院生物制药教研室正在研发的治疗RA的重组基因工程抗体药物,是以抗引起RA主要致炎因子IL-1β,IL-17为靶标的双价抗体药物,它的研制成功将填补国内治疗RA疾病的双价抗体药物的空白,缩短我国生物制药与世界总体制药水平的差距。为了保证生物技术药物的安全,有效和质量监控,需要进行临床前药理学的研究,动物模型的构建则是其中最为重要的组成环节之一,本研究的首要目的是建立能较全面反映RA特点的动物疾病模型。
IL-1β在RA炎的发病进程中的主要作用机理已经得到了明确的阐述,主要是使滑膜细胞和软骨细胞合成和释放胶原酶和其他蛋白溶解酶,并抑制软骨细胞合成蛋白多糖基质,从而在RA炎的发病进程中起重要作用;而近年来在RA病人滑膜上清液中发现大量存在的具有生物活性的IL-17,能显著促进炎症细胞分泌TNF-α、IL-1β,与其他炎症细胞因子有协同作用,间接促进RA炎症的发展。而多聚蛋白聚糖酶,即带有血小板凝血酶原敏感基序的解整连素和金属蛋白酶(a disintegrin and metalloproteinase with thrombospondin motifs,ADAMTS) ADAMTS-4对RA疾病中细胞外基质蛋白聚糖的降解起着重要的作用。在构建动物模型的基础上,本研究将通过IL-17诱导体外培养的软骨细胞,检测ADAMTS-4的表达情况,深入的研究IL-17在RA疾病中的是否在关节局部发挥直接作用,以期进一步探讨RA在分子水平的发病机理,更好的为创新药物的临床前药理学研究提供基础。
首先建立类风湿性关节炎动物模型,方法为:45只SD大鼠随机分成3组:免疫诱导组,免疫诱导加寒湿刺激组和对照组。免疫诱导组用鸡Ⅱ型胶原和弗氏完全佐剂乳化混合后0.25mL注入大鼠足跖部和背部皮下,7d后以0.1mL乳化剂加强免疫一次。寒湿刺激组在免疫诱导的基础上,每天将大鼠放入冰水中1h,连续14d。以相同体积的溶剂冰醋酸注射做为对照组。诱导后每周测量大鼠体重和足爪肿胀程度,21d和42d分别采集大鼠血清,测定抗Ⅱ型胶原抗体、TNF-α、IL-1β和IL-17表达水平,并对踝关节进行组织病理学、X-ray放射学检查。
成功建立RA的整体动物模型后,本研究进一步采用体外试验研究法,从分子水平单因素的考察IL-17在关节局部的致病作用,首先以胰蛋白酶和胶原酶两步消化法无菌取得大鼠软骨细胞,然后进行体外培养,经IL-17诱导后,在不同的时间点采集细胞样品,从蛋白质水平分析RA中IL-17能否诱导破坏软骨基质重要酶ADAMTS-4的表达,再从基因水平检测ADAMTS-4表达量的变化。具体试验方法为:将体外培养软骨细胞分为二组,即IL-17诱导组和未诱导对照组,分别取24h,48h的细胞培养上清液,离心后,采用蛋白质免疫印迹法检测ADAMTS-4蛋白质的表达情况,采用实时定量PCR法检测ADAMTS-4的mRNA的表达量的变化。首先采用Trizol法提取软骨细胞RNA,紫外分光光度仪测定RNA的OD值,并进行琼脂糖凝胶电泳检测提取RNA的质量。将质量合格的RNA逆转录为cDNA,采用PCR扩增ADAMTS-4片段,经琼脂糖凝胶电泳,紫外检测仪下观察PCR扩增结果。分别对两个时间点IL-17处理组软骨细胞与未处理组软骨细胞的cDNA在ABI 7500 real time PCR仪上进行实时定量PCR扩增,同时对每个样品做内参GAPDH的扩增。每个样品重复检测3次,用2-△ΔCt相对定量法分析其mRNA转录改变。
制备的类风湿性关节炎动物模型显示,试验大鼠在免疫后,足爪在次日严重红肿,随后肿胀逐渐消退,第7天加强免疫之后,双侧后足爪肿胀明显,前爪也发生继发性肿胀。胶原诱导组发病率为80%,胶原诱导加寒湿刺激组发病率为85%,溶剂对照组没有发病。与对照组相比,两个模型组间血清中抗CⅡ抗体、TNF-α、IL-1β和IL-17的水平均升高,差异极显著(P<0.01),而两个模型组的大鼠血清中抗CⅡ抗体、TNF-α、IL-1β和IL-17水平相比较,胶原诱导加寒湿刺激组比单纯诱导组稍有升高,但是差异不显著(P>0.05)。对照组的大鼠踝关节组织切片可见清晰的关节腔,而两个模型组大鼠踝关节组织切片可见滑膜细胞增生,排列疏散,紊乱,软骨细胞增生,关节腔可见炎性细胞浸润,滑膜组织中淋巴细胞严重浸润。发病大鼠踝关节处X光片的骨关节边缘模糊、软骨破坏、骨变形。
采用胰蛋白酶和胶原酶两步消化法成功获得原代的软骨细胞,对软骨细胞进行传代培养后,细胞生长状况良好,软骨细胞经冻存复苏后,活细胞率可以达到87%。经蛋白质免疫印迹分析表明,无论是经IL-17诱导还是未诱导组的软骨细胞均分泌表达ADAMTS-4蛋白,以Trizol法提取软骨细胞中的总RNA经鉴定纯度较好,经逆转录获得的cDNA为模版,以ADAMTS-4的上下游引物进行PCR扩增,可获得约99bp的预期长度的产物片段,条带清晰,无杂带。实时定量PCR检测致炎细胞因子IL-17诱导体外培养软骨细胞的ADAMTS-4的转录水平,发现破坏软骨细胞基质的ADAMTS-4的mRNA转录水平在诱导后24h和48h均显著升高,分别升高了6.37,8.62倍,与对照组相比差异极显著(P<0.01)。
通过对临床症状、关节炎指数、抗CⅡ抗体滴度、致炎细胞因子水平、组织病理变化和影像学变化的综合指标评价,本研究成功建立了大鼠类风湿性关节炎疾病模型,为创新药物的临床前研究奠定了基础。在RA整体动物模型中,以ELISA方法检测发现发病大鼠血清中IL-1β、IL-17的水平与对照组相比显著升高,说明创新药物构建的双价抗体以这两种致炎因子为靶标,将会有效的阻断RA的炎症进程。由于本研究旨在为抗IL-1β、IL-17双价的基因工程抗体药物的临床前药理学研究提供基础,考虑到整体动物模型体内环境复杂,为排除各种其他因素的干扰,本研究在体外进行软骨细胞的培养,通过进一步的体外试验研究表明,IL-17诱导组与未诱导组的软骨细胞培养上清液中均可以检测到ADAMTS-4蛋白的表达,实时定量PCR分析结果表明IL-17诱导组软骨细胞ADAMTS-4的表达量明显升高,与未诱导组的差异显著,可以推测在RA患者体内IL-17除了可以通过促进炎症细胞因子TNF-α、IL-1β的分泌,间接促进炎症发展以外,它还可以在关节局部直接通过诱导软骨细胞分泌ADAMTS-4来降解软骨中的蛋白聚糖,破坏软骨基质,使RA患者关节局部发生畸形,甚至残疾,从而在RA病症进程中发挥间接和直接的重要作用,可以推测阻断IL-17的作用是RA治疗中的一个潜在作用靶点,有可能成为有效筛选治疗RA有效药物的方式之一。
Rheumatoid arthritis (RA ) is a kind of chronic autoimmune disease charactered by astrosynovitis and destructive astropathy. There has been no specific therapeutics. The drug of geneticallyengineered antibody researched by the staff of biotechnology college in Northeast Agricultural University will make up a deficiency in the two-potency antibody drug treatment for the RA in China and reduce the difference in biotechnology drug between China and internation. The preclinical pharmacology research will provide the guarantee for the safety, effect and quality control of the biotechnology drug. The aim of this research is to prepare the animal disease models which reflect the features of RA and further to study its pathogenesis. This research provides the foundation for the preclinical pharmacological research of the orininal new drug.
The action target of drug was the IL-1βand IL-17 which are the main proinflammatory factor in RA. The mechanism of IL-1βin RA has been clearly explained, that is mainly induced the synoviocyte and chondrocyte expression the collagenase and other protease and inhibition the synthesis of proteoglycan. IL-17, recent years finding in the synovium supernatant of RA patient, can significantly promote the secretion of TNF-αand IL-1β. The aggrecanase(a disintegrin and metalloproteinase with thrombospondin motifs,ADAMTS) ADAMTS-4 can degradate the extracell matrix in cartilage. This research will culture the chondrocyte, and induce them with IL-17, then determine the ADAMTS-4 protein expression and mRAN change level. The aim of this research is to investigate the action mechanism of IL-17 in a local joint and further analyze the pathogeny of rheumatoid arthritis on the molecular level. This will supply a solid base for preclinical pharmacology research of the orinal drug.
Firstly, the whole animl desease model was established. 45 male SD rat were divided into 3 groups: simply immune-induced group; immune-induced and cold wetness-stimulated group; control group. Collagen-induced arthritic rat were intradermally immunized at the base of the tail with 0.25 mL of the emulsion containing chicken typeⅡcollagen and Freund’s complete adjuvant. On day 7 after the initial collagen immunization, the rats were intraperitoneally boosted with 0.1mL emulsion. Rat in immune-induced and cold wetness-stimulated group put in ice-water 1h for 10 days based on the immune with emulsion.The same volume of vehicle (glacial acetic acid)was administered as a control.Weight body and engorgement of foot and calw measured each week. Serum collected on 21d and 42d after initial collagen immunization for the determination of antibody for collagenⅡ; TNF-α; IL-1βand IL-17. Rats were euthanized by cervical dislocation on day 42 after initial collagen immunization. Histopathological features of peripheral ankles were assessed in hematoxylin-stained formalin-fixed paraffin-embedded sections. 5 rats in each group on day 42 after immune were anestetized by ethylether for radiological examination.
Chondrocytes were isolated from articular cartilage of rats and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 20% fetal bovine serum. Chondrocytes were serum-starved in DMEM for 24h and treated with IL-17for another 24h or 48h. RNA was extracted by the guanidinium isothiocyanate procedure and reverse-transcribed. The resulting cDNA was used as a template for qRT-PCR for primers designed using ADAMTS-4 gene sequence. Expression of ADAMTS-4 was analysed, as well as the house keeping gene GAPDH to normalize expresⅡon between different samples relative mRNA levels of ADAMTS-4 were determined using the fomula 2-△ΔCt. The conditioned media were concentrated to SDS–PAGE under reduction and immunoblotted with anti-ADAMTS-4 antibody.the development of the blots was carried out using the ECL plus chemiluminescence substrate.
After initial immune, the behind paws and joint were redness and swelling on the afterday, and then fadeaway gradually. After the boosted immune the whole paws and joint were swere inflammation. The disease incidence in simply immune-induced group was 80%; in immune-induced and cold wetness-stimulated group 85%. The solvent control group had no sequence inflammation.the levels of anticollagen antibody TNF-α; IL-1βand IL-17 in rat serum increased, and the difference were significece compared with control group (P<0.01).
Rat ankle joint cavity of tissue sections in control group can be seen clearly; proliferation of synovial cell and chondrocyte in treated group can be seen. Inflammatory cell infiltrated into the joint cavity and lymphocyte infiltrated into the synovium tissue. Radiographs demonstrate marginal erosion, blurred joint and cartilage damage.
After primary chondrocytes inoculation, under microscope, a large number of round cells in suspension, and had strong refraction, adherent cell Adherent cell body were flat, triangle or polygon, monolayer and mixed together gradually.the passage chondrocyte adherented completely within 24h. After freeze and recovery, the rate of living chondrocyte was 87%.
All chondrocyte was found to express mRNA for ADAMTS-4. ADAMTS-4 in 20h and 48h group showed a statistically significant increase (P<0.01) in mRNA expression levels following induction of IL-17, respectively, 6.37 and 8.62 folds. The protein of ADAMTS-4 in chondrocyte showed the positive result using the western blotting.
This research has prepared succeedfully the rheumatoid arthritis disease model with the following evaluation target: clinical symptom; arthritis index; the level of anticollagen antibody; TNF-α; IL-1βand IL-17; histopathology and radiological examination. The further research indicated that the IL-17 can induce the expression increase of the destructive enzyme-ADAMTS-4 and play an important role in the approaching destruction of cartilage matrix in rheumatoid arthritis. IL-17 could be the theruapeutic target.
In the animal desease model, the level of IL-1β、IL-17 increased significantly compared to the control group. Consideration the environment was complex in vivo desease model, chondrocytes were cultured and induced with IL-17 in vitro in order to avoid the interferers of many factor. The results indicated directly that IL-17 can induce the chondrocyte expression the ADAMTS-4, which degradate the extra cell matrix in cartilage of local joint and resultly the abnormity of joint and even crippledom happened. This illustrate that blocking the action of Il-17 in RA promptly will treat effectly the symptom of rheumatoid arthritis.
IL-1β在RA炎的发病进程中的主要作用机理已经得到了明确的阐述,主要是使滑膜细胞和软骨细胞合成和释放胶原酶和其他蛋白溶解酶,并抑制软骨细胞合成蛋白多糖基质,从而在RA炎的发病进程中起重要作用;而近年来在RA病人滑膜上清液中发现大量存在的具有生物活性的IL-17,能显著促进炎症细胞分泌TNF-α、IL-1β,与其他炎症细胞因子有协同作用,间接促进RA炎症的发展。而多聚蛋白聚糖酶,即带有血小板凝血酶原敏感基序的解整连素和金属蛋白酶(a disintegrin and metalloproteinase with thrombospondin motifs,ADAMTS) ADAMTS-4对RA疾病中细胞外基质蛋白聚糖的降解起着重要的作用。在构建动物模型的基础上,本研究将通过IL-17诱导体外培养的软骨细胞,检测ADAMTS-4的表达情况,深入的研究IL-17在RA疾病中的是否在关节局部发挥直接作用,以期进一步探讨RA在分子水平的发病机理,更好的为创新药物的临床前药理学研究提供基础。
首先建立类风湿性关节炎动物模型,方法为:45只SD大鼠随机分成3组:免疫诱导组,免疫诱导加寒湿刺激组和对照组。免疫诱导组用鸡Ⅱ型胶原和弗氏完全佐剂乳化混合后0.25mL注入大鼠足跖部和背部皮下,7d后以0.1mL乳化剂加强免疫一次。寒湿刺激组在免疫诱导的基础上,每天将大鼠放入冰水中1h,连续14d。以相同体积的溶剂冰醋酸注射做为对照组。诱导后每周测量大鼠体重和足爪肿胀程度,21d和42d分别采集大鼠血清,测定抗Ⅱ型胶原抗体、TNF-α、IL-1β和IL-17表达水平,并对踝关节进行组织病理学、X-ray放射学检查。
成功建立RA的整体动物模型后,本研究进一步采用体外试验研究法,从分子水平单因素的考察IL-17在关节局部的致病作用,首先以胰蛋白酶和胶原酶两步消化法无菌取得大鼠软骨细胞,然后进行体外培养,经IL-17诱导后,在不同的时间点采集细胞样品,从蛋白质水平分析RA中IL-17能否诱导破坏软骨基质重要酶ADAMTS-4的表达,再从基因水平检测ADAMTS-4表达量的变化。具体试验方法为:将体外培养软骨细胞分为二组,即IL-17诱导组和未诱导对照组,分别取24h,48h的细胞培养上清液,离心后,采用蛋白质免疫印迹法检测ADAMTS-4蛋白质的表达情况,采用实时定量PCR法检测ADAMTS-4的mRNA的表达量的变化。首先采用Trizol法提取软骨细胞RNA,紫外分光光度仪测定RNA的OD值,并进行琼脂糖凝胶电泳检测提取RNA的质量。将质量合格的RNA逆转录为cDNA,采用PCR扩增ADAMTS-4片段,经琼脂糖凝胶电泳,紫外检测仪下观察PCR扩增结果。分别对两个时间点IL-17处理组软骨细胞与未处理组软骨细胞的cDNA在ABI 7500 real time PCR仪上进行实时定量PCR扩增,同时对每个样品做内参GAPDH的扩增。每个样品重复检测3次,用2-△ΔCt相对定量法分析其mRNA转录改变。
制备的类风湿性关节炎动物模型显示,试验大鼠在免疫后,足爪在次日严重红肿,随后肿胀逐渐消退,第7天加强免疫之后,双侧后足爪肿胀明显,前爪也发生继发性肿胀。胶原诱导组发病率为80%,胶原诱导加寒湿刺激组发病率为85%,溶剂对照组没有发病。与对照组相比,两个模型组间血清中抗CⅡ抗体、TNF-α、IL-1β和IL-17的水平均升高,差异极显著(P<0.01),而两个模型组的大鼠血清中抗CⅡ抗体、TNF-α、IL-1β和IL-17水平相比较,胶原诱导加寒湿刺激组比单纯诱导组稍有升高,但是差异不显著(P>0.05)。对照组的大鼠踝关节组织切片可见清晰的关节腔,而两个模型组大鼠踝关节组织切片可见滑膜细胞增生,排列疏散,紊乱,软骨细胞增生,关节腔可见炎性细胞浸润,滑膜组织中淋巴细胞严重浸润。发病大鼠踝关节处X光片的骨关节边缘模糊、软骨破坏、骨变形。
采用胰蛋白酶和胶原酶两步消化法成功获得原代的软骨细胞,对软骨细胞进行传代培养后,细胞生长状况良好,软骨细胞经冻存复苏后,活细胞率可以达到87%。经蛋白质免疫印迹分析表明,无论是经IL-17诱导还是未诱导组的软骨细胞均分泌表达ADAMTS-4蛋白,以Trizol法提取软骨细胞中的总RNA经鉴定纯度较好,经逆转录获得的cDNA为模版,以ADAMTS-4的上下游引物进行PCR扩增,可获得约99bp的预期长度的产物片段,条带清晰,无杂带。实时定量PCR检测致炎细胞因子IL-17诱导体外培养软骨细胞的ADAMTS-4的转录水平,发现破坏软骨细胞基质的ADAMTS-4的mRNA转录水平在诱导后24h和48h均显著升高,分别升高了6.37,8.62倍,与对照组相比差异极显著(P<0.01)。
通过对临床症状、关节炎指数、抗CⅡ抗体滴度、致炎细胞因子水平、组织病理变化和影像学变化的综合指标评价,本研究成功建立了大鼠类风湿性关节炎疾病模型,为创新药物的临床前研究奠定了基础。在RA整体动物模型中,以ELISA方法检测发现发病大鼠血清中IL-1β、IL-17的水平与对照组相比显著升高,说明创新药物构建的双价抗体以这两种致炎因子为靶标,将会有效的阻断RA的炎症进程。由于本研究旨在为抗IL-1β、IL-17双价的基因工程抗体药物的临床前药理学研究提供基础,考虑到整体动物模型体内环境复杂,为排除各种其他因素的干扰,本研究在体外进行软骨细胞的培养,通过进一步的体外试验研究表明,IL-17诱导组与未诱导组的软骨细胞培养上清液中均可以检测到ADAMTS-4蛋白的表达,实时定量PCR分析结果表明IL-17诱导组软骨细胞ADAMTS-4的表达量明显升高,与未诱导组的差异显著,可以推测在RA患者体内IL-17除了可以通过促进炎症细胞因子TNF-α、IL-1β的分泌,间接促进炎症发展以外,它还可以在关节局部直接通过诱导软骨细胞分泌ADAMTS-4来降解软骨中的蛋白聚糖,破坏软骨基质,使RA患者关节局部发生畸形,甚至残疾,从而在RA病症进程中发挥间接和直接的重要作用,可以推测阻断IL-17的作用是RA治疗中的一个潜在作用靶点,有可能成为有效筛选治疗RA有效药物的方式之一。
Rheumatoid arthritis (RA ) is a kind of chronic autoimmune disease charactered by astrosynovitis and destructive astropathy. There has been no specific therapeutics. The drug of geneticallyengineered antibody researched by the staff of biotechnology college in Northeast Agricultural University will make up a deficiency in the two-potency antibody drug treatment for the RA in China and reduce the difference in biotechnology drug between China and internation. The preclinical pharmacology research will provide the guarantee for the safety, effect and quality control of the biotechnology drug. The aim of this research is to prepare the animal disease models which reflect the features of RA and further to study its pathogenesis. This research provides the foundation for the preclinical pharmacological research of the orininal new drug.
The action target of drug was the IL-1βand IL-17 which are the main proinflammatory factor in RA. The mechanism of IL-1βin RA has been clearly explained, that is mainly induced the synoviocyte and chondrocyte expression the collagenase and other protease and inhibition the synthesis of proteoglycan. IL-17, recent years finding in the synovium supernatant of RA patient, can significantly promote the secretion of TNF-αand IL-1β. The aggrecanase(a disintegrin and metalloproteinase with thrombospondin motifs,ADAMTS) ADAMTS-4 can degradate the extracell matrix in cartilage. This research will culture the chondrocyte, and induce them with IL-17, then determine the ADAMTS-4 protein expression and mRAN change level. The aim of this research is to investigate the action mechanism of IL-17 in a local joint and further analyze the pathogeny of rheumatoid arthritis on the molecular level. This will supply a solid base for preclinical pharmacology research of the orinal drug.
Firstly, the whole animl desease model was established. 45 male SD rat were divided into 3 groups: simply immune-induced group; immune-induced and cold wetness-stimulated group; control group. Collagen-induced arthritic rat were intradermally immunized at the base of the tail with 0.25 mL of the emulsion containing chicken typeⅡcollagen and Freund’s complete adjuvant. On day 7 after the initial collagen immunization, the rats were intraperitoneally boosted with 0.1mL emulsion. Rat in immune-induced and cold wetness-stimulated group put in ice-water 1h for 10 days based on the immune with emulsion.The same volume of vehicle (glacial acetic acid)was administered as a control.Weight body and engorgement of foot and calw measured each week. Serum collected on 21d and 42d after initial collagen immunization for the determination of antibody for collagenⅡ; TNF-α; IL-1βand IL-17. Rats were euthanized by cervical dislocation on day 42 after initial collagen immunization. Histopathological features of peripheral ankles were assessed in hematoxylin-stained formalin-fixed paraffin-embedded sections. 5 rats in each group on day 42 after immune were anestetized by ethylether for radiological examination.
Chondrocytes were isolated from articular cartilage of rats and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 20% fetal bovine serum. Chondrocytes were serum-starved in DMEM for 24h and treated with IL-17for another 24h or 48h. RNA was extracted by the guanidinium isothiocyanate procedure and reverse-transcribed. The resulting cDNA was used as a template for qRT-PCR for primers designed using ADAMTS-4 gene sequence. Expression of ADAMTS-4 was analysed, as well as the house keeping gene GAPDH to normalize expresⅡon between different samples relative mRNA levels of ADAMTS-4 were determined using the fomula 2-△ΔCt. The conditioned media were concentrated to SDS–PAGE under reduction and immunoblotted with anti-ADAMTS-4 antibody.the development of the blots was carried out using the ECL plus chemiluminescence substrate.
After initial immune, the behind paws and joint were redness and swelling on the afterday, and then fadeaway gradually. After the boosted immune the whole paws and joint were swere inflammation. The disease incidence in simply immune-induced group was 80%; in immune-induced and cold wetness-stimulated group 85%. The solvent control group had no sequence inflammation.the levels of anticollagen antibody TNF-α; IL-1βand IL-17 in rat serum increased, and the difference were significece compared with control group (P<0.01).
Rat ankle joint cavity of tissue sections in control group can be seen clearly; proliferation of synovial cell and chondrocyte in treated group can be seen. Inflammatory cell infiltrated into the joint cavity and lymphocyte infiltrated into the synovium tissue. Radiographs demonstrate marginal erosion, blurred joint and cartilage damage.
After primary chondrocytes inoculation, under microscope, a large number of round cells in suspension, and had strong refraction, adherent cell Adherent cell body were flat, triangle or polygon, monolayer and mixed together gradually.the passage chondrocyte adherented completely within 24h. After freeze and recovery, the rate of living chondrocyte was 87%.
All chondrocyte was found to express mRNA for ADAMTS-4. ADAMTS-4 in 20h and 48h group showed a statistically significant increase (P<0.01) in mRNA expression levels following induction of IL-17, respectively, 6.37 and 8.62 folds. The protein of ADAMTS-4 in chondrocyte showed the positive result using the western blotting.
This research has prepared succeedfully the rheumatoid arthritis disease model with the following evaluation target: clinical symptom; arthritis index; the level of anticollagen antibody; TNF-α; IL-1βand IL-17; histopathology and radiological examination. The further research indicated that the IL-17 can induce the expression increase of the destructive enzyme-ADAMTS-4 and play an important role in the approaching destruction of cartilage matrix in rheumatoid arthritis. IL-17 could be the theruapeutic target.
In the animal desease model, the level of IL-1β、IL-17 increased significantly compared to the control group. Consideration the environment was complex in vivo desease model, chondrocytes were cultured and induced with IL-17 in vitro in order to avoid the interferers of many factor. The results indicated directly that IL-17 can induce the chondrocyte expression the ADAMTS-4, which degradate the extra cell matrix in cartilage of local joint and resultly the abnormity of joint and even crippledom happened. This illustrate that blocking the action of Il-17 in RA promptly will treat effectly the symptom of rheumatoid arthritis.
引文
艾景录,吕爱平,徐世杰等. 1995.性腺功能异常型肾虚痹证发生机理的实验研究[J].中国中医基础医学杂志[J]. 1(1): 42
曹亚. 2003.实用分子生物学操作指南.北京:人发卫生出版主社. 1~50
查道德,张妍蓓. Toll样受体和核因子-κB与肿瘤[J].临床肺科杂志, 2008. 13(7): 894~7
陈晓宇,陈明,李俊.2006. MAPKs信号转导在类风湿性关节炎滑膜细胞中的作用[J].中国药理学通报, 22(12): 1424~8
邓军卫,吴轰,李芬等. 2000.HLA-Ⅱ类基因DRα及DRB1 0401转基因小鼠模型的遗传与繁殖[J].中国实验动物学报. 8(1): 36~40
高红,王贵新. 2006.用蛋白印迹技术初步评价肝细胞瘤血管内皮生长因子表达的意义[J].中华小儿外科杂志. (27):61
郭尧君. 2006.蛋白质电泳实验技术[M].北京:科学出版社. 276~284
韩晓枫,马宝骊等. 2001.胶原Ⅱ型诱导大鼠类风关模型的建立[J].上海免疫学杂志. 6(21):330~333
韩星海,孟济明. 2003.生物制剂在类风湿关节炎中的应用[J].中华风湿病学杂志. 7(5):300~301
黄乃艳.2000.类风湿性关节炎的动物模型[J].激光生物学报. 9(2):142
李思远,曹峻岭,师钟丽. 2004.多聚蛋白聚糖酶与骨关节疾病[J].生命的化学. 24(1):55~56
李晓军,秦浚传,武建国. 2004.蛋白印迹技术研究进展[J].临床检验杂志. (22): 227
李仪奎. 1991.中药药理实验方法学[M].上海:上海科学技术出版社. 3
李亦蕾,郭甫坤,吴曙光.2000.白介素-1受体相关激酶-2反义寡核苷酸对白介素-1和肿瘤坏死因子激活核因子-κB的不同影响[J].中国药理学通报,16(3):319~21
廖满林,廖穗波. 2007.类风湿性关节炎患者IL-1α, IL-1β, IL-17与护骨因子水平检测及临床意义[J].广东医学杂志. 1(28): 109~110
林红,贺永怀,黎燕等. 2006.Ⅱ型胶原蛋白与弗氏完全佐剂大鼠关节炎模型的建立和比较[J].中国实验动物学报. 1(7): 1~6
刘建文. 2003.药理学实验方法学-新技术新方法.北京:化学工业出版社. 149~154
刘琼,王晨瑶,方剑乔. 2006.类风湿性关节炎动物模型的研究进展[J].医学综述. 3(12): 313~316
刘森. 2009. PCR聚合酶链反应.北京:化学工业出版社. 87~109
刘元刚,刘树滔,饶平凡. 2007.类风湿性关节炎啮齿动物模型的研究进展[J].中国实验动物学报. 6(15): 470~473
吕爱平.2000.关节软骨免疫与类风湿性关节炎Ⅱ型胶原所致免疫性关节炎发病机制[J].中化风湿病学杂志. 5(6):1
吕社民. 2006.用动物模型定位、克隆复杂性疾病的易感基因:以类风湿关节炎动物模型为例[J].西安交通大学学报. 5(27): 417~420
宁旭,尚显文,尹培荣等. 2004.胶原酶一次消化法培养兔软骨细胞[J].贵洲医学杂志. l24(6): 490~492
彭程,肖涛,罗远明等. 2008. IGF-1对IL-1诱导的兔关节软骨细胞NO和PGE2的影响[J].中南大学学报(医学版). 33(3): 197
沈关心,龚非力.2006.抗体技术实验指南[M].北京:科学出版社. 203~218
司徒镇强,吴军正. 2007.细胞培养[M].西安:世界图书出版公司. 49~81
宋永周,崔慧先,吕哲等. 2008.大鼠关节软骨细胞的培养[J].河北医科大学学报. 29(4): 534~537
唐碧霞,张烜,唐福林. 2008. IL-17与自身免疫性疾病关系的研究进展[J].基础医学与临床. 1(28):94~97
田新平,蒋明. 1997. HLAZDR基因与类风湿风湿性关节炎[J].中华内科杂志. 36(7): 495~497
王安民,吕爱平,曾晓莲. 1988.大鼠实验性痹证模型建立及其病理学研究[J].中华中医骨伤科杂志. 4(2): 8
王斌,唐福林. 2001.类风湿关节炎治疗进展[J].山西医药杂志. 30(1): 34~38
王春田,于静. 2003.类风湿关节炎动物模型研究进展[J].辽宁中医杂志. 30(6): 511~512
王金发,何炎明. 2004.细胞生物学实验教程.北京:科学出版社101~109
王绪辉. 1986.肢体痹证的造模方法[J].上海中医药杂志. (3):3
王云,王礼文. 2007.免疫细胞及细胞因子在类风湿性关节炎中的致病机制研究进展[J].中国康复医学杂志. 22(4): 370~374
肖长虹,顾为望,李留洋等. 1996.类风湿性关节炎风寒湿痹与风湿热痹动物模型研究[J].中医杂志. 6(37): 361
熊国林,黄海潇等. 2007.类风湿性关节炎大鼠模型的制备[J].解放军医学杂志. 2(32): 121~123
于孟学,王迎雪,施全胜. 1998.类风湿性关节炎发病机理[J].基础医学与临床. 18(4): 2~5
张金宇. 1998.类风湿性关节炎[J].北京医药杂志. 524~526.
张燕婉,叶珏,时那等. 2008.蛋白质免疫印迹技术的实验研究实[J].验技术与管理. 25(10): 35~40
张义浜,刘志敏,熊凌霜. 2005.类风湿性关节炎发病机制及其治疗方法研究进展[J].细胞与分子免疫学杂志. 21: 88~94
张元兴,易小萍,张立等. 2006.动物细胞培养工程[M].北京:化学工业出版社. 1~8
张锃锃,韩晓枫,金坚. 2006.Ⅱ型胶原诱导的类风湿关节炎大鼠模型的建立[J].免疫学杂志. 5(22): 552~558
张志光,郑卫平,苏凯等. 2004.兔关节软骨细胞的分离培养学特征[J].中山大学报:医学科学版. 25(1):63
赵晓俞,李继刚. 2006.实用分子生物学技术。北京:化学工业出版社,33~48
中华医学会风湿病学分会. 2003.类风湿性关节炎诊治指南(草案)[J].中华风湿病学杂志. 7(4): 145
朱乃硕,王亚新,王福庆. 1994.中国人群HLAZDR4等位基因结构及其与RA相关性研究[J].中华医学杂志. 14(7): 428~29
邹耀红. 2003. NSAIDs在风湿性疾病中的应用[J].中国处方药. 10:62~65
A.K. Cross, G. Haddock, J. Surr, J. Plumb, R.A.D. Bunning, D.J. Buttle et al 2006. Differential Expression of ADAMTS-1, -4, -5 and TIMP-3 in Rat Spinal Cord at Different Stages of Acute Experimental Autoimmune Encephalomyelitis. Journal of Autoimmunity, 26(1): 1243~1252
Abbaszade H, Liu RQ, Yang FD, Rosenfeld SA, Ross OH, et al. 1999. Cloning and Characterization of ADAMTS11, an aggrecanase from the ADAMTS Family[J]. J Biol Chem 274: 23443~23450
Ahbeg A, Henricson AS, Telhag HT, et al. 1978. Effect of Osmium Tetroxide and on normal and arthritis rabbit knee joints [J].Scand J Rheumatol. 7:21~25
Anderson, KM Cheung PH, Kell MD. 1997. Rapid gene ration of homologous interna standards and evaluation of data for quantitaion of messenger RNA by cempetitive Polymerase chain reaetion. J Pharmaeol Toxicol Methods[J]. 38: 133~140
Anthony N. Corps, Gavin C. Jones, Rebecca L.Harrall et al. 2008. The regulation of aggrecanase ADAMTS-4 expression in human Achilles tendon and tendon-derived cells [J]. Matrix Biol. 27(5): 393~401
Arend, WP. 2001. Cytokine imbalance in the pathogenesis of rheumatoid arthritis:the role of interliulin-1 receptor antagonist. Semin Arthritis Rheurn, 30(Suppl 2):1~6.
Arend, WP. 2001.Cytokine imbalance in the pathogenesis of rheumatoid arthritis:the role of in-terliulin-1 receptor antagonist[J]. Semin ArthritisRheurn, 30:1~6
Aringer M, Graninger WB. 2002.Treating rheumatoid arthritis with new disease modifying drugs[J].Acta Med Austriaca, 29(1): 33~35
Attur MG,Patel NR,Abrason SB,Amin AR. 1997. Interleukin-17 up-regulation of nitric oxide produetion in humano steoarthritis cartilage.Arthritis Rheum, 40: 1050~1053.
Barnes DA, Tse J,Kaufhold M,et al. 1998. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewisrat adjuvant-induced arthritis model[J].Clin Invest, 101(12):2910~2919
Basu S, Binder RJ, Suto R, et al. 2000. Necrotic but not apoptoticcell death releases heat shock proteins,which deliver a partialmaturation signal to dendritic cells and activate the NF-κBpathway[J].Int Immunol, 12:1539~1546
Bausero MA, Gastpar R, Multhoff G et al. 2005. Alternative mechanism by which IFN-γenhances tumor recognition: active release of heat shock protein 72[J].J Immunol, 175:2900~2912
Beeker K., D. Pan and C.B. Whitely. 1999. Real time quantitative Polymerase chain reaetion to assess gene transfer. Hum.GeneTher., 10: 2559~2566
Berenbaum, F., Jacques, C., Thomas, G. 1996. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes does not involve PLA2 stimulation [J]. Exp. Cell Res. 222, 379~384
Birkedal-Hansen H., W. G. Moore, M. K. Bodden, et al. 1993. Matrix metalloproteinases: a review.Crit Rev.Oral Biol.Med.4:197~250
Black, R. A., Kronheim, S. R., Cantrell, M. et al. 1988. Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactiveprecursor [J]. J. Biol. Chem., 263: 9437~9442
Boers M. 1995. The validity of radiography as outcome measure inrheumatoid arthritis[J].Rheumatol, 22:1783
BrittbergM, LindahlA, NilssonA, et al. 1994. Treatment of deep cartilage defects in the knee with autologous chondroeytes transplantation [J].N Engl J Med, 331:893
Budker V, Zhang G, Danko I, Willams P, et al. 1998.The efficient expression of intravascularly delivered DNA in rat muscle. Gene Ther. 5:272~276
Burkhardt H, Sehnert B, Bockermann R,et al. 2005. Humoral immune response to citrullinated collagen typeⅡdeterminants inearly rheumatoid arthritis[J]. Immunol, 35:1643~1652.
CaiL, Yin JP, StarovasnikMA, et al. 2001. Pathways by which interleukin-17 induces articular cartilage breakdown in vitro and in vivo [J].Cytokine. 16(1):10~21
Camussi G, Lupia E. 1998.The Future Role of Anti-tumournecrosis Factor Products in the Treatment of Rheumatoid Arthritis[J]. Drugs, 55:613~620
Carlsen S. 1998.Cartilage oligomeric matrix protein(COMP)-induced arthritis in rats[J].Clin Exp Immunol. 114: 477~484 Catchpole B, Hamblin AS, Staines NA. 2001.T cell lines generated with typeⅡcollagen
proliferate in an autologous mixed lymphocyte response[J].Autoimmu. 17:181~189.
Chin J E, Lin YA. 1988. Effects of recombinant human interleukin-1 beta on rabbit articular chond-rocytes.Stimulation of prostanoid release and inhi-bition of cell growth [J].Arthritis Rheum. 31(10):1290~1296.
Claire Jacques, Marjolaine Gosset, Francis Berenbaum et al. 2006. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation [J]. Vitamins and Hormones, 74: 371~403
Clayton A, Turkes A, Navabi H,et al.2005.Induction of heatshock proteins in B-cell exosomes[J].J Cell Sci. 118:3631~3638.
Cohen S, Hurd E, Cush J,et al. 2002.Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1receptor antagonist, in combination with methotrexate: re-sults of a twenty-four-week, multicenter, randomized,double-blind,placebo-controlled trial[J].Arthritis Rheum. 46:614~624.
Conn DL. 2003. New role for an old friend:prednisone is a disease.modifying agent in earlyrheumatoid arthritis[J].Current Opinion in Rheumatology.15:193~196.
Cooke TD,Hurd ER, Ziff M,et al. 1972.The pathogensis of chronic inf1ammation in experiment antigen induced arthritis.Ⅱ.preferential 1ocalizations of antigen antibody complexes to collagenous tissues. J Exp Med. 135:323~338.
Corinne Granet, Alain Guignandon Laurence Vico, et al. 2002. MAP and src kinases control the induction of AP-1 members in response to changes in mechanical environment in osteoblastic cells [J]. Cellular Signalling. 14 (8): 679~688
Crofford, L. J., Lipsky, P. E., Brooks, P., et al. 2004. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors[J]. Arthritis Rheum. 3, 4~13
Cross A, Bucknall RC, Cassatella MA, et al. 2003. Synovial fluidneutrophils transcribe and express classⅡmajor histocompati-bility complex molecules in rheumatoid arthritis[J]. Arthritis Rheum. 48: 2796~2806
Davis John C. 2004. Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis[J]. Seminars inArthritis and Rheumatism. 34:668~677.
Dibattista JA, Martel Pelletier J,Wosu LO, et al. 1991.Glucocorticoid receptormediated inhibition of interleukin-1 stimulated neutral metal loprote asesynthesis in normal human chondrocytes[J]. Clin Endocrinol Metab. 72(2):316~326
Dinarello, C.A. Biologic basis for interleukin-1 in disease [J] Blood, 1996, 87(6): 2095-2147 Dudler J, RenggliZulliger N,Busso N, et al. 2000. Effectof interleukin-17 on proteoglycan degradation inmurine knee joints [J].Ann Rheum-Dis. 597:529~532
Edwands SW, Hallett MB. 1997. Seeing the wood forthe trees:the forgotten role of neutrophils in rheumatoid arthritis[J]. Immunol Today. 18(7):320~324.
Edwrd K, Janice W, Panl G, et al. 1998.The role of IL-10 in rheumatoid arthritis[J]. Rheum Dis Clin North Am. 24(3):629~63
Ehrenstein MR., Evans JG, Singh A, et al. 2004. Compromised function of regulatory T cells in rheumatoid arthritis andreversal by anti-TNFa therapy [J].J Exp.Med. 200:277~285
Enslen H, Brancho DM, Davis RJ. 2000. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms[J]. EMBO J. 15, 19(6):1301~11
Ernst E. 2003.complementary medicine.Curr Opin Rheumatol. 15:151~5
Faten Merhi-Soussia, Marina Bertia, Bernhard Wehrle-Hallerb et al. 2005. Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1αprecursor on cell motility [J]. Cytokine. 32, (3~4), 163~170
Feld mann M, Andreakos E, Smith C,et al. 2002. Is NF-κB a use-ful therapeutic target in rheumatoid arthritis [J]. Ann RheumDis, 61(suppl) 2: 13~18
Feldmann M. 1996. The Cytokine Network in Rheumatoid Arthritis: Definition of TNF alpha as a Therapeutic Target [J]. R Coll Physicians Lond. 30:560~570
Fitzgerald ML, Wang Z, Park PW, et al. 2000. Shedding of syndecan-1 and-4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.JCell Biol. 148(4):811~824
Flannery CR, Zeng W, Corcoran C, et al. 2002. Autocatalytic cleavage of ADAMTS~4 (Aggrecanase-1)reveals multiple glycosaminoglycan-binding sites.J Biol Chem,277:42775~42780
Fleshner M, Johnson JD. 2005. Exogenous extracellular heatshock protein 72: releasing signal and function [J].Int JHyperthermia. 21:457~471
Fosang AJ, Last K, Knauper V, Neame PJ, et al 1993. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J, 295: 273~276
Freed LE, Grande DA, Lingbin Z, et al. 1994. Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds[J]. J Biomed Mater Res. 28~31
Gabriel, S.E. 2001. The epidemiology of rheumatoid arthritis[J].Rheum Dis.Clin.North Am. 27. 269~282
Gao G, Plaas A,Thompson VP,et al. 2004. ADAMTS4(aggrecanase-1)activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1[J].J Biol Chem. 279:10042~10051
Gary SF. 2003. Evolving concepts of rheumatoid arthritis. N ature, 423:356~361
Goupille, P., Jayson, M. I., Valat, J. P. et al. 1998. Matrix metalloproteinases:The clue to intervertebral disc degeneration[J]. Spine, 23. 1612~1626
Grewal IS,Flavell RA. 1996. A central role of CD40 ligand in the regulation of CD4+T cell responses [J].Immunol Today. 17(9):410~414
Gustavo Bombini, Claudio Canetti, Rocha F, et al. 2004.Tumour Necrosis Factor Mediates Neutrophil Migration to theKnee Synovial Cavity during Immune inflammation.Pharmacology. 496:197~204
Han, Z, Boyle, DL, Chang,L. et al. 2001. C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis[J]. The Journal of Clinical Investigation. 108(1): 73~81
Hashimoto G, Nakamura H, Nakamura H, et al. 2001. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Letters. 494:192~195
HauriH P, Bucher K. 1988. Immunoblotting with monoclonal antibodies: Importance of the blocking solution [J].Anal Biochem. (159): 386~389
Henderson B,Pettipher ER. 1989. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo[J].Clin Exp Immunol. 75(2):306~310
Henicson AS, Telhag HT, Wollheim FAO.1982. Smium tetroxide in antigen induced arthritis:failure to inhibit joint destruction[J]. Acta Orthop Scand. 53:17~21
Highton J, Guevremont D, Schofield J, et al. 1997. Antigen induced (Dumonde Glynn)arthritis in the sheep: a large joint animal model of arthritis[J]. Clin Exp Rheumatol. 15:23~31
Honorati MC, Cattini L, Facchini A. 2004. IL-17, IL-1 and TNF-a stimulateVEGF production by dedifferentiated chondrocytes [ J].OsteoarthritisCartilage. 12(9):683~692
Horasu, Pclinkovic D, Hersg, et al. 2003. Autologous chondrocyte implantation and chondral cylinder transplantation in cartilagerepair of the knee joint [J]. J Bone Joint Surg, 85(2): 185~192
Hu, B., Wang, S., Zhang, Y. et al. 2003. Anuclear target for interleukin‐ 1alpha: Interaction with the growth suppressor necdin modulates proliferation and collagen expression [J]. Proc. Natl. Acad. Sci. USA, 100. 1008~10013
Hulkower KI, Wertheimer SJ, Levin W. 1994. Interleukin-1 beta induces cytosolic phospholipase A2 and prostagland in Hsynthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostagland in E2 [J]. Arthritis Rheum. 37(5): 653~661
Jeffery J. Maclean, Peter J. Roughley, Robert D. Monsey et al. 2008. In vivo intervertebral disc remodeling: kinetics of mRAN expression in response to a single loading event[J] J Orthop Res. 26(5): 579~588
Jose AL,Maria AO,Eduardo P, et al. 1995. Therapetic effect of recombinant vaccinia virus expressing the 60 kD heat shock protein on adjuvant arthritis [J].Arthritis Rheum, 38:129~138
Jovanovic DV, Fernandes JC, Martel-Pelletier J, et al. 2001. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis.Arthritis Rheum. 44:2320~2330
Kamradt T, Schubert D. 2005. The role and clinical implications of G6PI in experimental models of rheumatoid arthritis [J].Arthritis Res Ther. 7: 20~28
Kavanaugh AF, Davis LS, Nichols LA, et al. 1994.Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1(ICAM-1)[J]. Arthritis Rheum. 37:992~999
Kim Wu, Cho ML, Jung Yo,et al. 2004. TypeⅡcollagen autoimmuning in rhermatoid arthritis[J].Am J Med Sci. 327: 202~211
Kinne RW, Brauer R, Stuhlmuller B et al. 2000. Macrophages inrheumatoid arthritis[J]. Arthritis Res. 2:189~202
KonttinenYT, Ainola M Valleala H et al. 1999. Analysis of 16 different matrix metallo proteinases (MMP-1 to MMP-20) in the synovial melnbrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 58: 691~697
Koshy PJ, Lundy CJ, Rowan AD, et al., 2002. The modulation of matrix metalloproteinase andADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M:a time-course study using real-time quantitative reverse transcription-polymerase chain reaction.Arthritis Rheum. 46(4):961~967
KotakeN, Udagawa N, TakahashiN, et al. 1999. IL-17 in synovial fluidsform paients with rheumatoid arthritis is a potent stimulator of oste-oclastogenesis[J].Clin Inves. 103(3)L1345~1352
Kuga S, Otsuka T, NⅡro H, et al. 1996. Suppression of superoxide anion production by interleukin-10 is accompanied by a down regulation of thegenes for sudunit proteins of NADPH oxidase[J].Exp Hematol. 24(2):151~157
Kunisch E, Gandesiri M, Fuhrmann R et al. 2007. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis[J]. Ann Rheum Dis. 66(8): 1043~51
Larsson P, Kleinau S, Holmdahl R, et al. 1990. Homologous typeⅡcollagen-induced arthritis in rats[J]. Arthritis Rheum. 33: 693~701
Le Maitre CL, Freemont AJ, Hoyland JA. 2005. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration.Arthritis Res Ther. 7:R732~745
LeGrand A, Fermor B, Fink C, et al. 2001. Interleukin-1,tumor necrosisfactor alpha, and interleukin-17 synergistically upregulate nitricoxide and prostagland in E2 prouction in explants of human os-teoar-thritic kneemenisci[ J]. Arthritis Rheum. 44(9): 2078~2083
Leonard Calabrese, Alan B DO, Fleischer. 2000. Thalidomide:Current and Potential Clinical Applications[J]. The American Journal of Medicine. 108: 487~495
Lindy O, Y. T. Konttinen, T. Sorsa, Y. Ding, et al. 1997. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum. 40:1391~1399
Lipsky PE, Van der Heijde DM, St Clair EW,et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthri-tis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group[J]. N Engl JMed. 343: 1594~1602
Lotz M, Blanco FJ, von Kempis J, et al. 1995. Cytokine regulation of chondrocyte functions.J Rheumatol Suppl. 43:104~108
Luke AJ O’Neill. 2006. How Toll-like receptors signal: what we know and what we don’t know [J]. Current Opinion in Immunology. 18(1), 3~9
Lyodak, Miura J, Nogami H. 1993. Repair of bone defect with cultured chondrocytes bond to hydroxyapatite [J].Clin orthop. 288:289
Manieourt Dh, Poilvache P, Nzeusseu A et al. 1999. Serum levels of hyaluxonan, antigen keratin sulfate, matrix metalloproteinase 3, and tissue inbitor of metalloproteinases1 change predietably in rheumatoid arthritis Patients who have begun aetivity after a night of bed rest. Arthritis Rheum. 42:1861~1869
Manning WK, Bonner WM. 1967. Isolation and culture of chondrocytes from human articular cartilage [J]. Arthritis Rheum. 10(3):235~239
Martel-Pelletier J, Mineau F,Jovanovie D, DiBattista JA. 1999. Mitogen activated protein kinase and nuelear factor kappa B together regulate interleukin-17-induced nitric oxide Produetion in human osteoarthritie chondroeytes.Arthritis Rheum. 42: 2399~2409
Martin CA, Carsons SE, Kowalewski R,et al. 2003.Aberrant Extracellular and Dendritic Cell (DC)Surface Expression of Heat Shock Protein(hsp)70 in the Rheumatoid Joint: PossibleMechanisms of hsp/DC-Mediated Cross-Priming [J]. Immunol. 171: 5736~5742
McInnes IB, Liew FY. 2005. Cytokine networks-towards newtherapies for rheumatoid arthritis[J]. NatClin PractRheumatoid. 1: 31~39
Mecklenburgh KI, Walmsley SR, Cowburn AS,et al. 2002. Involvement of a ferroprotein sensor in hypoxia mediated inhibition of neutrophil apoptosis [J].Blood. 100: 3008~3016
MI Koenders, E Lubberts, LAB Joosten et al. 2004. IL-1-dependent cartilage damage in a macrophage-driven arthritis model can be circumvented by T cell IL-17 Arthritis Res Ther 6(Suppl 1):30
Morel JC; Park CC; Zhu K. 2002. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression[J]. The Journal of Biological Chemistry. 277(38): 34679~91
Murphy G., V. Knauper, S. Atkinson, G. Butler, et al 2002. Matrix metalloproteinases in arthritic disease. Arthritis Res.4 Suppl 3: S39~S49
NⅡro H,Otsuka T,Izuhara K,et al. 1997. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils[J].Blood, 89(5):1621~1628
NⅡro H, Otsuka T,Tanabe T, et al. 1995.Inhibition by interleukin-10 of inducible cyclooxygenase expression in ipoplysaccharide-stimulatedmonocytes:Its underlying mechanism in comparison with interleukin-4[J]. Blood. 85(12):3736~3745
Newkirk MM. 2002. Rheumatoid factors: what do they tell us.Rheumatol. 29: 2034~2040
Niki, Y., Yamada, H., Kikuchi, T. et al. 2004. Membrane-associated IL-1 contributes to chronic synovitis and cartilage destructionin human IL-1 alpha transgenic mice [J]. J. Immunol., 172: 577~584
Nishikawa M, Myoui A, Tomita T, et al. 2003. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR1676531[J]. Arthritis Rheum., 48(9): 2670~81
Numasaki M, Fukushi J, et al. 2003. Interleukin-17 promotes angiogenesis and tumor growth[J]. Blood. 101(7):735~738
Ollier W, Winehester R.1999. The germline and somatic genetic basis of rhteumatoid arthritis. Genes and Genetics of Autoimmunity Basel, Switzerlnad: Karger. 166~193
Olsen N,Sokka T,Seehorn CL,et al. 2004. A gene expressionsignature for recent oncet rheumatoid arthritis in peripheralblood mononuclear cells[J].Ann of the Rheum Dis, 63:1387~1392
Pelletier JP,Boileau C,Boily M,et al. 2005. The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors:MMP-13,cathepsin K and aggrecanases[J]. Arthritis Res Ther. 7(5):R1091~R1102
Perlman H, Bradley K, Liu H T, et al. 2003. IL-6 and MatrixMetalloproteinase-1 Are Regulated by the Cyclin-DependentKinase Inhibitor p21 in Synovial Fibroblasts[J].Immunol, 170: 838~845
Puelacher WC, Kim WS, Vacanti JP, et al. 1994. Tissue-engineeredgrowth of cartilage: the effect of varying the concentration of chondrocytes seeded onto synthetic polymer matrice[J]. Int J Oral Maxillofac Surg, 23~49
Rasheed Ahmada, Judith Sylvestera and Muhammad Zafarullah. 2007. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1 induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase[J]. Cellular Signalling, 19(12): 2549~2557
Ratkay LG,Chowdhary RK,Iamaroon A, et al. 1998. Amelioration of antigen induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy[J]. Arthritis Rheum. 41: 525~534
Reiser H,Stadecker MJ. 1996.Costimulatory B7 molecules in the pathogenesis of infectiousand autoimmune diseases[J].New Eng J Med, 335(18):1369~1377
Ryu S,Lee JH,Kim SI. 2006.IL-17 increased the production of vascularendothelial growth factor in rheumatoid arthritis synoviocytes[J].ClinRheumato, 25(1):16~20
Samantha A, Oblander, Robert P.T.et al. 2003. An update on metalloproteases in the musculoskeletal system.Current Opinion in Orthopaedics, 14:322~328
Sarah PORTER, Ian M. CLARK. Lara KEVORKIAN et al. 2005. the ADAMTS metalloproteinases[J]. Biochem J, 366: 15~27
Saxine T,Pallading MA,Heinegand D,et al. 1988.Detection ofTNF-αbut not TNF-βin RA synovial fluid and serum[J].Arthritis Rheum, 31:1041~1045
Scheel-Toellner D, Wang K, Henriquez NV et al. 2002. Cytokine-mediated inhibition of apoptosis in non-transformed T cellsand neutrophils can be dissociated from protein kinase B acti-vation[J]. Eur J Immunol: 32: 486~493
Scott DL. 2002. Advances in the medical management of rheumatoid arthritis[J].Hosp Med. 63(5): 294~297
Silverman GJ, Carson DA. 2003. Roles of B cells in rheumatoid arthritis[J]. Arthritis Res Ther, 5 (suppl). 4:S1~S6
Stichtenoth, D. O., Thoren, S., Bian, H. 2001. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells [J]. J. Immunol, 167: 469~474
Szekanca Z, Koch AE, Kunkel SL,et al. 1998.Cytokine in rheumatoid arthritis potential targetsfor pharmacological intervention[J]. Drugs Aging, 12(3):337~387
Szekanca Z,Koch AE,Kunkel SL,et al. 1998. Cytokine in rheumatoid arthritis potential targetsfor pharmacological intervention. J Drugs Aging, 12(3):337~387
Taneja V, Taneja N, Paisansinsup T, et al. 2002. CD4 and CD8T cells in susceptibllity/protection to collagen-induced arthritisin HLA-DQ8-transgenic mice:implications for rheumatoid arthritis.[J].J Immunol, 168: 5867~5875
Tang BL. 2000. ADAMTS:a novel family of extracellular matrix protease. Int J Biochem Cell Biol 33:33~44
Tania Azam, Daniela Novick, Philip Bufler, et al. Identification of a critical Ig-like domain in IL-18 receptorαand characterization of a functional IL-18 receptor complex [J]. The Journal of Immunology, 2003, 171: 6574~6580
Thentham DE,Alexander S,David E,et al. 1997.Autoimmunity to typeⅡcollagen: an experimental model of arthritis[J ].Exp Med, 146:857~868
Thomas D.Sehmittgen, Brian A Zakrajsek, Alan G. Mills, et al. 2000. Quantitative Reverse Transcription Polymerase Chain reaetion to Study mRNA Decay: Comparison of Endpoint and real time methods. Analytical Bioehemistry[J]. 285:194~204
Tortorella M D, Burn T C, Pratta M A,et al. 1999,Purification andcloning of aggrecanase-1: a member of the ADAMTS family of roteins. Science, 284: 1664~1666
Tovey ER, Baldo BA. 1987. Characterisation of allergens by protein bloting[J]. Electrophoresis, (8): 452~463
Towbin H, Gordon J. 1984. Immunoblotting and dot immunobinding:current status and outlook [ J]. ImmunolMethods, (72):313~340
Towbin H, Staehelin T, Gordon.. 1979. Electrophoretic transfer of pro-teins from polyacrylamide gels to nitrocellulose sheets. Procedurand some applications[J]. Proc Natl Acal Sci USA, (76):4350~4354
Trauner KB, Gandour Edwards R, Bamberg M, et al. 1998.Photodynamic synovectomy using benzoporphyrin derivative in an antigen induced arthritis model for rheumatoid arthritis[J].Photochemistry and Photobiology, 67:133~139
Trauner KB,Gandour Edwards R, Bamberg M, et al. 1998.Influence of light synovectomy in an antigen induced arthritis model for rheumatoid arthritis[J].Lasers in Surgery and Medicine, 22:147~156
Trentham DE.Townes AS,Kang AH. 1977.Autoimmunity to type ll collagen:an experimental model of arthritis[J]. Exp Med, 164:857~867
Van't, Hof-RJ, Armour, KJ, Smith, LM, et al. Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption [J]. Proc. Natl. Acad. Sci. USA, 2000, 97(14): 7993~7998
Vincenti, M. P. and C. E. Brinckerhoff. 2002. Transcriptional regulation of collagenase (MMP-1,MMP-13) genes in arthritis: integration of complexsignaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res.4:157~164
Vossenaar ER, Van Venrooij WJ. 2004. Citrullinated proteins:sparks that may ignite the fire in rheumatoid arthritis[J].Arthritis Res Ther,6: 107~111
Wang P,Tortorella M,England K,et al. 2004. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4(Aggrecanase-1)in the trans-Golgi network.J BiolChem, 279:15434~15440
Whalen JD,Lechman EL,Carlos CA,et al. 1999. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen induced arthritis in both injected anduninjected paws[J].Immunol, 162(6):3625~3632
William PA. 1997.The pathophysiology and treatment of rheumatoid arthritis[J]. Arthritis Rheum, 40(4):595~597
Wollheim FA,Telhag H,Henricesson A,et al. 1994. Prevention ofjoint destruction in antigen induced arthritis. Clin Immuno1Immunopatho1, 70:19~21
Wollheim FA,Telhag H,Henricesson A,et al. 1994.Prevention of joint destruction in antigen induced arthritis[J]. Clin Immuno1 Immunopatho1. 70:19~21
Wong S H, Lord JM. 2004. Factors underlying chronic inflammationin rheumatoid arthritis[J]. Arch Immunol Ther Exp, 52, 379~388
Wooley PH. 2004. Immunotherapy in collagen-induced arthritis: past,present,and future[J].Am J Med Sci. 327:217~226
Yamanishi Y, Boyle DL, Clark M, et al.,Expression and regulation of aggrecanase in arthritis:the role of TGF-beta.J Immunol. 2002. 168: 1405~1412
Yelin E, Wanke LA. 1999. An assessment of annual and long-term direct costs:the impact of poor functional decline[J].Arthritis Rheum. 42:1209~18
Yu WH, Yu S,Meng Q,et al. 2000,TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix.J Biol Chem. 275(40):31226~31232
Zhang G, Virikko KI,Myllyla R,et al. 2002.Surgical Procedure for intravascular delivery of plasmid DNA to organs.Methods Enzymol. 346:125~133
Zhang ZJ, Lee-Christopher SY, Lider O, et al. 1990.Suppression of adjuvantarthritis in Lewis rats by oral administration of typeⅡcollagen[J]. Immunol. 145:2489
Zini N; Lisignoli G; Solimando L. Maraldi NM. 2003. IL1-beta and TNF-alpha induce changes in the nuclear polyphosphoinositide signalling system in osteoblasts similar to that occurring in patients with rheumatoid arthritis: an immunochemical and immunocytochemical study [J]. Histochemistry and cell biology. 120: 243~250
曹亚. 2003.实用分子生物学操作指南.北京:人发卫生出版主社. 1~50
查道德,张妍蓓. Toll样受体和核因子-κB与肿瘤[J].临床肺科杂志, 2008. 13(7): 894~7
陈晓宇,陈明,李俊.2006. MAPKs信号转导在类风湿性关节炎滑膜细胞中的作用[J].中国药理学通报, 22(12): 1424~8
邓军卫,吴轰,李芬等. 2000.HLA-Ⅱ类基因DRα及DRB1 0401转基因小鼠模型的遗传与繁殖[J].中国实验动物学报. 8(1): 36~40
高红,王贵新. 2006.用蛋白印迹技术初步评价肝细胞瘤血管内皮生长因子表达的意义[J].中华小儿外科杂志. (27):61
郭尧君. 2006.蛋白质电泳实验技术[M].北京:科学出版社. 276~284
韩晓枫,马宝骊等. 2001.胶原Ⅱ型诱导大鼠类风关模型的建立[J].上海免疫学杂志. 6(21):330~333
韩星海,孟济明. 2003.生物制剂在类风湿关节炎中的应用[J].中华风湿病学杂志. 7(5):300~301
黄乃艳.2000.类风湿性关节炎的动物模型[J].激光生物学报. 9(2):142
李思远,曹峻岭,师钟丽. 2004.多聚蛋白聚糖酶与骨关节疾病[J].生命的化学. 24(1):55~56
李晓军,秦浚传,武建国. 2004.蛋白印迹技术研究进展[J].临床检验杂志. (22): 227
李仪奎. 1991.中药药理实验方法学[M].上海:上海科学技术出版社. 3
李亦蕾,郭甫坤,吴曙光.2000.白介素-1受体相关激酶-2反义寡核苷酸对白介素-1和肿瘤坏死因子激活核因子-κB的不同影响[J].中国药理学通报,16(3):319~21
廖满林,廖穗波. 2007.类风湿性关节炎患者IL-1α, IL-1β, IL-17与护骨因子水平检测及临床意义[J].广东医学杂志. 1(28): 109~110
林红,贺永怀,黎燕等. 2006.Ⅱ型胶原蛋白与弗氏完全佐剂大鼠关节炎模型的建立和比较[J].中国实验动物学报. 1(7): 1~6
刘建文. 2003.药理学实验方法学-新技术新方法.北京:化学工业出版社. 149~154
刘琼,王晨瑶,方剑乔. 2006.类风湿性关节炎动物模型的研究进展[J].医学综述. 3(12): 313~316
刘森. 2009. PCR聚合酶链反应.北京:化学工业出版社. 87~109
刘元刚,刘树滔,饶平凡. 2007.类风湿性关节炎啮齿动物模型的研究进展[J].中国实验动物学报. 6(15): 470~473
吕爱平.2000.关节软骨免疫与类风湿性关节炎Ⅱ型胶原所致免疫性关节炎发病机制[J].中化风湿病学杂志. 5(6):1
吕社民. 2006.用动物模型定位、克隆复杂性疾病的易感基因:以类风湿关节炎动物模型为例[J].西安交通大学学报. 5(27): 417~420
宁旭,尚显文,尹培荣等. 2004.胶原酶一次消化法培养兔软骨细胞[J].贵洲医学杂志. l24(6): 490~492
彭程,肖涛,罗远明等. 2008. IGF-1对IL-1诱导的兔关节软骨细胞NO和PGE2的影响[J].中南大学学报(医学版). 33(3): 197
沈关心,龚非力.2006.抗体技术实验指南[M].北京:科学出版社. 203~218
司徒镇强,吴军正. 2007.细胞培养[M].西安:世界图书出版公司. 49~81
宋永周,崔慧先,吕哲等. 2008.大鼠关节软骨细胞的培养[J].河北医科大学学报. 29(4): 534~537
唐碧霞,张烜,唐福林. 2008. IL-17与自身免疫性疾病关系的研究进展[J].基础医学与临床. 1(28):94~97
田新平,蒋明. 1997. HLAZDR基因与类风湿风湿性关节炎[J].中华内科杂志. 36(7): 495~497
王安民,吕爱平,曾晓莲. 1988.大鼠实验性痹证模型建立及其病理学研究[J].中华中医骨伤科杂志. 4(2): 8
王斌,唐福林. 2001.类风湿关节炎治疗进展[J].山西医药杂志. 30(1): 34~38
王春田,于静. 2003.类风湿关节炎动物模型研究进展[J].辽宁中医杂志. 30(6): 511~512
王金发,何炎明. 2004.细胞生物学实验教程.北京:科学出版社101~109
王绪辉. 1986.肢体痹证的造模方法[J].上海中医药杂志. (3):3
王云,王礼文. 2007.免疫细胞及细胞因子在类风湿性关节炎中的致病机制研究进展[J].中国康复医学杂志. 22(4): 370~374
肖长虹,顾为望,李留洋等. 1996.类风湿性关节炎风寒湿痹与风湿热痹动物模型研究[J].中医杂志. 6(37): 361
熊国林,黄海潇等. 2007.类风湿性关节炎大鼠模型的制备[J].解放军医学杂志. 2(32): 121~123
于孟学,王迎雪,施全胜. 1998.类风湿性关节炎发病机理[J].基础医学与临床. 18(4): 2~5
张金宇. 1998.类风湿性关节炎[J].北京医药杂志. 524~526.
张燕婉,叶珏,时那等. 2008.蛋白质免疫印迹技术的实验研究实[J].验技术与管理. 25(10): 35~40
张义浜,刘志敏,熊凌霜. 2005.类风湿性关节炎发病机制及其治疗方法研究进展[J].细胞与分子免疫学杂志. 21: 88~94
张元兴,易小萍,张立等. 2006.动物细胞培养工程[M].北京:化学工业出版社. 1~8
张锃锃,韩晓枫,金坚. 2006.Ⅱ型胶原诱导的类风湿关节炎大鼠模型的建立[J].免疫学杂志. 5(22): 552~558
张志光,郑卫平,苏凯等. 2004.兔关节软骨细胞的分离培养学特征[J].中山大学报:医学科学版. 25(1):63
赵晓俞,李继刚. 2006.实用分子生物学技术。北京:化学工业出版社,33~48
中华医学会风湿病学分会. 2003.类风湿性关节炎诊治指南(草案)[J].中华风湿病学杂志. 7(4): 145
朱乃硕,王亚新,王福庆. 1994.中国人群HLAZDR4等位基因结构及其与RA相关性研究[J].中华医学杂志. 14(7): 428~29
邹耀红. 2003. NSAIDs在风湿性疾病中的应用[J].中国处方药. 10:62~65
A.K. Cross, G. Haddock, J. Surr, J. Plumb, R.A.D. Bunning, D.J. Buttle et al 2006. Differential Expression of ADAMTS-1, -4, -5 and TIMP-3 in Rat Spinal Cord at Different Stages of Acute Experimental Autoimmune Encephalomyelitis. Journal of Autoimmunity, 26(1): 1243~1252
Abbaszade H, Liu RQ, Yang FD, Rosenfeld SA, Ross OH, et al. 1999. Cloning and Characterization of ADAMTS11, an aggrecanase from the ADAMTS Family[J]. J Biol Chem 274: 23443~23450
Ahbeg A, Henricson AS, Telhag HT, et al. 1978. Effect of Osmium Tetroxide and on normal and arthritis rabbit knee joints [J].Scand J Rheumatol. 7:21~25
Anderson, KM Cheung PH, Kell MD. 1997. Rapid gene ration of homologous interna standards and evaluation of data for quantitaion of messenger RNA by cempetitive Polymerase chain reaetion. J Pharmaeol Toxicol Methods[J]. 38: 133~140
Anthony N. Corps, Gavin C. Jones, Rebecca L.Harrall et al. 2008. The regulation of aggrecanase ADAMTS-4 expression in human Achilles tendon and tendon-derived cells [J]. Matrix Biol. 27(5): 393~401
Arend, WP. 2001. Cytokine imbalance in the pathogenesis of rheumatoid arthritis:the role of interliulin-1 receptor antagonist. Semin Arthritis Rheurn, 30(Suppl 2):1~6.
Arend, WP. 2001.Cytokine imbalance in the pathogenesis of rheumatoid arthritis:the role of in-terliulin-1 receptor antagonist[J]. Semin ArthritisRheurn, 30:1~6
Aringer M, Graninger WB. 2002.Treating rheumatoid arthritis with new disease modifying drugs[J].Acta Med Austriaca, 29(1): 33~35
Attur MG,Patel NR,Abrason SB,Amin AR. 1997. Interleukin-17 up-regulation of nitric oxide produetion in humano steoarthritis cartilage.Arthritis Rheum, 40: 1050~1053.
Barnes DA, Tse J,Kaufhold M,et al. 1998. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewisrat adjuvant-induced arthritis model[J].Clin Invest, 101(12):2910~2919
Basu S, Binder RJ, Suto R, et al. 2000. Necrotic but not apoptoticcell death releases heat shock proteins,which deliver a partialmaturation signal to dendritic cells and activate the NF-κBpathway[J].Int Immunol, 12:1539~1546
Bausero MA, Gastpar R, Multhoff G et al. 2005. Alternative mechanism by which IFN-γenhances tumor recognition: active release of heat shock protein 72[J].J Immunol, 175:2900~2912
Beeker K., D. Pan and C.B. Whitely. 1999. Real time quantitative Polymerase chain reaetion to assess gene transfer. Hum.GeneTher., 10: 2559~2566
Berenbaum, F., Jacques, C., Thomas, G. 1996. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes does not involve PLA2 stimulation [J]. Exp. Cell Res. 222, 379~384
Birkedal-Hansen H., W. G. Moore, M. K. Bodden, et al. 1993. Matrix metalloproteinases: a review.Crit Rev.Oral Biol.Med.4:197~250
Black, R. A., Kronheim, S. R., Cantrell, M. et al. 1988. Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactiveprecursor [J]. J. Biol. Chem., 263: 9437~9442
Boers M. 1995. The validity of radiography as outcome measure inrheumatoid arthritis[J].Rheumatol, 22:1783
BrittbergM, LindahlA, NilssonA, et al. 1994. Treatment of deep cartilage defects in the knee with autologous chondroeytes transplantation [J].N Engl J Med, 331:893
Budker V, Zhang G, Danko I, Willams P, et al. 1998.The efficient expression of intravascularly delivered DNA in rat muscle. Gene Ther. 5:272~276
Burkhardt H, Sehnert B, Bockermann R,et al. 2005. Humoral immune response to citrullinated collagen typeⅡdeterminants inearly rheumatoid arthritis[J]. Immunol, 35:1643~1652.
CaiL, Yin JP, StarovasnikMA, et al. 2001. Pathways by which interleukin-17 induces articular cartilage breakdown in vitro and in vivo [J].Cytokine. 16(1):10~21
Camussi G, Lupia E. 1998.The Future Role of Anti-tumournecrosis Factor Products in the Treatment of Rheumatoid Arthritis[J]. Drugs, 55:613~620
Carlsen S. 1998.Cartilage oligomeric matrix protein(COMP)-induced arthritis in rats[J].Clin Exp Immunol. 114: 477~484 Catchpole B, Hamblin AS, Staines NA. 2001.T cell lines generated with typeⅡcollagen
proliferate in an autologous mixed lymphocyte response[J].Autoimmu. 17:181~189.
Chin J E, Lin YA. 1988. Effects of recombinant human interleukin-1 beta on rabbit articular chond-rocytes.Stimulation of prostanoid release and inhi-bition of cell growth [J].Arthritis Rheum. 31(10):1290~1296.
Claire Jacques, Marjolaine Gosset, Francis Berenbaum et al. 2006. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation [J]. Vitamins and Hormones, 74: 371~403
Clayton A, Turkes A, Navabi H,et al.2005.Induction of heatshock proteins in B-cell exosomes[J].J Cell Sci. 118:3631~3638.
Cohen S, Hurd E, Cush J,et al. 2002.Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1receptor antagonist, in combination with methotrexate: re-sults of a twenty-four-week, multicenter, randomized,double-blind,placebo-controlled trial[J].Arthritis Rheum. 46:614~624.
Conn DL. 2003. New role for an old friend:prednisone is a disease.modifying agent in earlyrheumatoid arthritis[J].Current Opinion in Rheumatology.15:193~196.
Cooke TD,Hurd ER, Ziff M,et al. 1972.The pathogensis of chronic inf1ammation in experiment antigen induced arthritis.Ⅱ.preferential 1ocalizations of antigen antibody complexes to collagenous tissues. J Exp Med. 135:323~338.
Corinne Granet, Alain Guignandon Laurence Vico, et al. 2002. MAP and src kinases control the induction of AP-1 members in response to changes in mechanical environment in osteoblastic cells [J]. Cellular Signalling. 14 (8): 679~688
Crofford, L. J., Lipsky, P. E., Brooks, P., et al. 2004. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors[J]. Arthritis Rheum. 3, 4~13
Cross A, Bucknall RC, Cassatella MA, et al. 2003. Synovial fluidneutrophils transcribe and express classⅡmajor histocompati-bility complex molecules in rheumatoid arthritis[J]. Arthritis Rheum. 48: 2796~2806
Davis John C. 2004. Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis[J]. Seminars inArthritis and Rheumatism. 34:668~677.
Dibattista JA, Martel Pelletier J,Wosu LO, et al. 1991.Glucocorticoid receptormediated inhibition of interleukin-1 stimulated neutral metal loprote asesynthesis in normal human chondrocytes[J]. Clin Endocrinol Metab. 72(2):316~326
Dinarello, C.A. Biologic basis for interleukin-1 in disease [J] Blood, 1996, 87(6): 2095-2147 Dudler J, RenggliZulliger N,Busso N, et al. 2000. Effectof interleukin-17 on proteoglycan degradation inmurine knee joints [J].Ann Rheum-Dis. 597:529~532
Edwands SW, Hallett MB. 1997. Seeing the wood forthe trees:the forgotten role of neutrophils in rheumatoid arthritis[J]. Immunol Today. 18(7):320~324.
Edwrd K, Janice W, Panl G, et al. 1998.The role of IL-10 in rheumatoid arthritis[J]. Rheum Dis Clin North Am. 24(3):629~63
Ehrenstein MR., Evans JG, Singh A, et al. 2004. Compromised function of regulatory T cells in rheumatoid arthritis andreversal by anti-TNFa therapy [J].J Exp.Med. 200:277~285
Enslen H, Brancho DM, Davis RJ. 2000. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms[J]. EMBO J. 15, 19(6):1301~11
Ernst E. 2003.complementary medicine.Curr Opin Rheumatol. 15:151~5
Faten Merhi-Soussia, Marina Bertia, Bernhard Wehrle-Hallerb et al. 2005. Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1αprecursor on cell motility [J]. Cytokine. 32, (3~4), 163~170
Feld mann M, Andreakos E, Smith C,et al. 2002. Is NF-κB a use-ful therapeutic target in rheumatoid arthritis [J]. Ann RheumDis, 61(suppl) 2: 13~18
Feldmann M. 1996. The Cytokine Network in Rheumatoid Arthritis: Definition of TNF alpha as a Therapeutic Target [J]. R Coll Physicians Lond. 30:560~570
Fitzgerald ML, Wang Z, Park PW, et al. 2000. Shedding of syndecan-1 and-4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.JCell Biol. 148(4):811~824
Flannery CR, Zeng W, Corcoran C, et al. 2002. Autocatalytic cleavage of ADAMTS~4 (Aggrecanase-1)reveals multiple glycosaminoglycan-binding sites.J Biol Chem,277:42775~42780
Fleshner M, Johnson JD. 2005. Exogenous extracellular heatshock protein 72: releasing signal and function [J].Int JHyperthermia. 21:457~471
Fosang AJ, Last K, Knauper V, Neame PJ, et al 1993. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J, 295: 273~276
Freed LE, Grande DA, Lingbin Z, et al. 1994. Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds[J]. J Biomed Mater Res. 28~31
Gabriel, S.E. 2001. The epidemiology of rheumatoid arthritis[J].Rheum Dis.Clin.North Am. 27. 269~282
Gao G, Plaas A,Thompson VP,et al. 2004. ADAMTS4(aggrecanase-1)activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1[J].J Biol Chem. 279:10042~10051
Gary SF. 2003. Evolving concepts of rheumatoid arthritis. N ature, 423:356~361
Goupille, P., Jayson, M. I., Valat, J. P. et al. 1998. Matrix metalloproteinases:The clue to intervertebral disc degeneration[J]. Spine, 23. 1612~1626
Grewal IS,Flavell RA. 1996. A central role of CD40 ligand in the regulation of CD4+T cell responses [J].Immunol Today. 17(9):410~414
Gustavo Bombini, Claudio Canetti, Rocha F, et al. 2004.Tumour Necrosis Factor Mediates Neutrophil Migration to theKnee Synovial Cavity during Immune inflammation.Pharmacology. 496:197~204
Han, Z, Boyle, DL, Chang,L. et al. 2001. C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis[J]. The Journal of Clinical Investigation. 108(1): 73~81
Hashimoto G, Nakamura H, Nakamura H, et al. 2001. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Letters. 494:192~195
HauriH P, Bucher K. 1988. Immunoblotting with monoclonal antibodies: Importance of the blocking solution [J].Anal Biochem. (159): 386~389
Henderson B,Pettipher ER. 1989. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo[J].Clin Exp Immunol. 75(2):306~310
Henicson AS, Telhag HT, Wollheim FAO.1982. Smium tetroxide in antigen induced arthritis:failure to inhibit joint destruction[J]. Acta Orthop Scand. 53:17~21
Highton J, Guevremont D, Schofield J, et al. 1997. Antigen induced (Dumonde Glynn)arthritis in the sheep: a large joint animal model of arthritis[J]. Clin Exp Rheumatol. 15:23~31
Honorati MC, Cattini L, Facchini A. 2004. IL-17, IL-1 and TNF-a stimulateVEGF production by dedifferentiated chondrocytes [ J].OsteoarthritisCartilage. 12(9):683~692
Horasu, Pclinkovic D, Hersg, et al. 2003. Autologous chondrocyte implantation and chondral cylinder transplantation in cartilagerepair of the knee joint [J]. J Bone Joint Surg, 85(2): 185~192
Hu, B., Wang, S., Zhang, Y. et al. 2003. Anuclear target for interleukin‐ 1alpha: Interaction with the growth suppressor necdin modulates proliferation and collagen expression [J]. Proc. Natl. Acad. Sci. USA, 100. 1008~10013
Hulkower KI, Wertheimer SJ, Levin W. 1994. Interleukin-1 beta induces cytosolic phospholipase A2 and prostagland in Hsynthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostagland in E2 [J]. Arthritis Rheum. 37(5): 653~661
Jeffery J. Maclean, Peter J. Roughley, Robert D. Monsey et al. 2008. In vivo intervertebral disc remodeling: kinetics of mRAN expression in response to a single loading event[J] J Orthop Res. 26(5): 579~588
Jose AL,Maria AO,Eduardo P, et al. 1995. Therapetic effect of recombinant vaccinia virus expressing the 60 kD heat shock protein on adjuvant arthritis [J].Arthritis Rheum, 38:129~138
Jovanovic DV, Fernandes JC, Martel-Pelletier J, et al. 2001. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis.Arthritis Rheum. 44:2320~2330
Kamradt T, Schubert D. 2005. The role and clinical implications of G6PI in experimental models of rheumatoid arthritis [J].Arthritis Res Ther. 7: 20~28
Kavanaugh AF, Davis LS, Nichols LA, et al. 1994.Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1(ICAM-1)[J]. Arthritis Rheum. 37:992~999
Kim Wu, Cho ML, Jung Yo,et al. 2004. TypeⅡcollagen autoimmuning in rhermatoid arthritis[J].Am J Med Sci. 327: 202~211
Kinne RW, Brauer R, Stuhlmuller B et al. 2000. Macrophages inrheumatoid arthritis[J]. Arthritis Res. 2:189~202
KonttinenYT, Ainola M Valleala H et al. 1999. Analysis of 16 different matrix metallo proteinases (MMP-1 to MMP-20) in the synovial melnbrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 58: 691~697
Koshy PJ, Lundy CJ, Rowan AD, et al., 2002. The modulation of matrix metalloproteinase andADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M:a time-course study using real-time quantitative reverse transcription-polymerase chain reaction.Arthritis Rheum. 46(4):961~967
KotakeN, Udagawa N, TakahashiN, et al. 1999. IL-17 in synovial fluidsform paients with rheumatoid arthritis is a potent stimulator of oste-oclastogenesis[J].Clin Inves. 103(3)L1345~1352
Kuga S, Otsuka T, NⅡro H, et al. 1996. Suppression of superoxide anion production by interleukin-10 is accompanied by a down regulation of thegenes for sudunit proteins of NADPH oxidase[J].Exp Hematol. 24(2):151~157
Kunisch E, Gandesiri M, Fuhrmann R et al. 2007. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis[J]. Ann Rheum Dis. 66(8): 1043~51
Larsson P, Kleinau S, Holmdahl R, et al. 1990. Homologous typeⅡcollagen-induced arthritis in rats[J]. Arthritis Rheum. 33: 693~701
Le Maitre CL, Freemont AJ, Hoyland JA. 2005. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration.Arthritis Res Ther. 7:R732~745
LeGrand A, Fermor B, Fink C, et al. 2001. Interleukin-1,tumor necrosisfactor alpha, and interleukin-17 synergistically upregulate nitricoxide and prostagland in E2 prouction in explants of human os-teoar-thritic kneemenisci[ J]. Arthritis Rheum. 44(9): 2078~2083
Leonard Calabrese, Alan B DO, Fleischer. 2000. Thalidomide:Current and Potential Clinical Applications[J]. The American Journal of Medicine. 108: 487~495
Lindy O, Y. T. Konttinen, T. Sorsa, Y. Ding, et al. 1997. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum. 40:1391~1399
Lipsky PE, Van der Heijde DM, St Clair EW,et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthri-tis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group[J]. N Engl JMed. 343: 1594~1602
Lotz M, Blanco FJ, von Kempis J, et al. 1995. Cytokine regulation of chondrocyte functions.J Rheumatol Suppl. 43:104~108
Luke AJ O’Neill. 2006. How Toll-like receptors signal: what we know and what we don’t know [J]. Current Opinion in Immunology. 18(1), 3~9
Lyodak, Miura J, Nogami H. 1993. Repair of bone defect with cultured chondrocytes bond to hydroxyapatite [J].Clin orthop. 288:289
Manieourt Dh, Poilvache P, Nzeusseu A et al. 1999. Serum levels of hyaluxonan, antigen keratin sulfate, matrix metalloproteinase 3, and tissue inbitor of metalloproteinases1 change predietably in rheumatoid arthritis Patients who have begun aetivity after a night of bed rest. Arthritis Rheum. 42:1861~1869
Manning WK, Bonner WM. 1967. Isolation and culture of chondrocytes from human articular cartilage [J]. Arthritis Rheum. 10(3):235~239
Martel-Pelletier J, Mineau F,Jovanovie D, DiBattista JA. 1999. Mitogen activated protein kinase and nuelear factor kappa B together regulate interleukin-17-induced nitric oxide Produetion in human osteoarthritie chondroeytes.Arthritis Rheum. 42: 2399~2409
Martin CA, Carsons SE, Kowalewski R,et al. 2003.Aberrant Extracellular and Dendritic Cell (DC)Surface Expression of Heat Shock Protein(hsp)70 in the Rheumatoid Joint: PossibleMechanisms of hsp/DC-Mediated Cross-Priming [J]. Immunol. 171: 5736~5742
McInnes IB, Liew FY. 2005. Cytokine networks-towards newtherapies for rheumatoid arthritis[J]. NatClin PractRheumatoid. 1: 31~39
Mecklenburgh KI, Walmsley SR, Cowburn AS,et al. 2002. Involvement of a ferroprotein sensor in hypoxia mediated inhibition of neutrophil apoptosis [J].Blood. 100: 3008~3016
MI Koenders, E Lubberts, LAB Joosten et al. 2004. IL-1-dependent cartilage damage in a macrophage-driven arthritis model can be circumvented by T cell IL-17 Arthritis Res Ther 6(Suppl 1):30
Morel JC; Park CC; Zhu K. 2002. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression[J]. The Journal of Biological Chemistry. 277(38): 34679~91
Murphy G., V. Knauper, S. Atkinson, G. Butler, et al 2002. Matrix metalloproteinases in arthritic disease. Arthritis Res.4 Suppl 3: S39~S49
NⅡro H,Otsuka T,Izuhara K,et al. 1997. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils[J].Blood, 89(5):1621~1628
NⅡro H, Otsuka T,Tanabe T, et al. 1995.Inhibition by interleukin-10 of inducible cyclooxygenase expression in ipoplysaccharide-stimulatedmonocytes:Its underlying mechanism in comparison with interleukin-4[J]. Blood. 85(12):3736~3745
Newkirk MM. 2002. Rheumatoid factors: what do they tell us.Rheumatol. 29: 2034~2040
Niki, Y., Yamada, H., Kikuchi, T. et al. 2004. Membrane-associated IL-1 contributes to chronic synovitis and cartilage destructionin human IL-1 alpha transgenic mice [J]. J. Immunol., 172: 577~584
Nishikawa M, Myoui A, Tomita T, et al. 2003. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR1676531[J]. Arthritis Rheum., 48(9): 2670~81
Numasaki M, Fukushi J, et al. 2003. Interleukin-17 promotes angiogenesis and tumor growth[J]. Blood. 101(7):735~738
Ollier W, Winehester R.1999. The germline and somatic genetic basis of rhteumatoid arthritis. Genes and Genetics of Autoimmunity Basel, Switzerlnad: Karger. 166~193
Olsen N,Sokka T,Seehorn CL,et al. 2004. A gene expressionsignature for recent oncet rheumatoid arthritis in peripheralblood mononuclear cells[J].Ann of the Rheum Dis, 63:1387~1392
Pelletier JP,Boileau C,Boily M,et al. 2005. The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors:MMP-13,cathepsin K and aggrecanases[J]. Arthritis Res Ther. 7(5):R1091~R1102
Perlman H, Bradley K, Liu H T, et al. 2003. IL-6 and MatrixMetalloproteinase-1 Are Regulated by the Cyclin-DependentKinase Inhibitor p21 in Synovial Fibroblasts[J].Immunol, 170: 838~845
Puelacher WC, Kim WS, Vacanti JP, et al. 1994. Tissue-engineeredgrowth of cartilage: the effect of varying the concentration of chondrocytes seeded onto synthetic polymer matrice[J]. Int J Oral Maxillofac Surg, 23~49
Rasheed Ahmada, Judith Sylvestera and Muhammad Zafarullah. 2007. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1 induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase[J]. Cellular Signalling, 19(12): 2549~2557
Ratkay LG,Chowdhary RK,Iamaroon A, et al. 1998. Amelioration of antigen induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy[J]. Arthritis Rheum. 41: 525~534
Reiser H,Stadecker MJ. 1996.Costimulatory B7 molecules in the pathogenesis of infectiousand autoimmune diseases[J].New Eng J Med, 335(18):1369~1377
Ryu S,Lee JH,Kim SI. 2006.IL-17 increased the production of vascularendothelial growth factor in rheumatoid arthritis synoviocytes[J].ClinRheumato, 25(1):16~20
Samantha A, Oblander, Robert P.T.et al. 2003. An update on metalloproteases in the musculoskeletal system.Current Opinion in Orthopaedics, 14:322~328
Sarah PORTER, Ian M. CLARK. Lara KEVORKIAN et al. 2005. the ADAMTS metalloproteinases[J]. Biochem J, 366: 15~27
Saxine T,Pallading MA,Heinegand D,et al. 1988.Detection ofTNF-αbut not TNF-βin RA synovial fluid and serum[J].Arthritis Rheum, 31:1041~1045
Scheel-Toellner D, Wang K, Henriquez NV et al. 2002. Cytokine-mediated inhibition of apoptosis in non-transformed T cellsand neutrophils can be dissociated from protein kinase B acti-vation[J]. Eur J Immunol: 32: 486~493
Scott DL. 2002. Advances in the medical management of rheumatoid arthritis[J].Hosp Med. 63(5): 294~297
Silverman GJ, Carson DA. 2003. Roles of B cells in rheumatoid arthritis[J]. Arthritis Res Ther, 5 (suppl). 4:S1~S6
Stichtenoth, D. O., Thoren, S., Bian, H. 2001. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells [J]. J. Immunol, 167: 469~474
Szekanca Z, Koch AE, Kunkel SL,et al. 1998.Cytokine in rheumatoid arthritis potential targetsfor pharmacological intervention[J]. Drugs Aging, 12(3):337~387
Szekanca Z,Koch AE,Kunkel SL,et al. 1998. Cytokine in rheumatoid arthritis potential targetsfor pharmacological intervention. J Drugs Aging, 12(3):337~387
Taneja V, Taneja N, Paisansinsup T, et al. 2002. CD4 and CD8T cells in susceptibllity/protection to collagen-induced arthritisin HLA-DQ8-transgenic mice:implications for rheumatoid arthritis.[J].J Immunol, 168: 5867~5875
Tang BL. 2000. ADAMTS:a novel family of extracellular matrix protease. Int J Biochem Cell Biol 33:33~44
Tania Azam, Daniela Novick, Philip Bufler, et al. Identification of a critical Ig-like domain in IL-18 receptorαand characterization of a functional IL-18 receptor complex [J]. The Journal of Immunology, 2003, 171: 6574~6580
Thentham DE,Alexander S,David E,et al. 1997.Autoimmunity to typeⅡcollagen: an experimental model of arthritis[J ].Exp Med, 146:857~868
Thomas D.Sehmittgen, Brian A Zakrajsek, Alan G. Mills, et al. 2000. Quantitative Reverse Transcription Polymerase Chain reaetion to Study mRNA Decay: Comparison of Endpoint and real time methods. Analytical Bioehemistry[J]. 285:194~204
Tortorella M D, Burn T C, Pratta M A,et al. 1999,Purification andcloning of aggrecanase-1: a member of the ADAMTS family of roteins. Science, 284: 1664~1666
Tovey ER, Baldo BA. 1987. Characterisation of allergens by protein bloting[J]. Electrophoresis, (8): 452~463
Towbin H, Gordon J. 1984. Immunoblotting and dot immunobinding:current status and outlook [ J]. ImmunolMethods, (72):313~340
Towbin H, Staehelin T, Gordon.. 1979. Electrophoretic transfer of pro-teins from polyacrylamide gels to nitrocellulose sheets. Procedurand some applications[J]. Proc Natl Acal Sci USA, (76):4350~4354
Trauner KB, Gandour Edwards R, Bamberg M, et al. 1998.Photodynamic synovectomy using benzoporphyrin derivative in an antigen induced arthritis model for rheumatoid arthritis[J].Photochemistry and Photobiology, 67:133~139
Trauner KB,Gandour Edwards R, Bamberg M, et al. 1998.Influence of light synovectomy in an antigen induced arthritis model for rheumatoid arthritis[J].Lasers in Surgery and Medicine, 22:147~156
Trentham DE.Townes AS,Kang AH. 1977.Autoimmunity to type ll collagen:an experimental model of arthritis[J]. Exp Med, 164:857~867
Van't, Hof-RJ, Armour, KJ, Smith, LM, et al. Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption [J]. Proc. Natl. Acad. Sci. USA, 2000, 97(14): 7993~7998
Vincenti, M. P. and C. E. Brinckerhoff. 2002. Transcriptional regulation of collagenase (MMP-1,MMP-13) genes in arthritis: integration of complexsignaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res.4:157~164
Vossenaar ER, Van Venrooij WJ. 2004. Citrullinated proteins:sparks that may ignite the fire in rheumatoid arthritis[J].Arthritis Res Ther,6: 107~111
Wang P,Tortorella M,England K,et al. 2004. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4(Aggrecanase-1)in the trans-Golgi network.J BiolChem, 279:15434~15440
Whalen JD,Lechman EL,Carlos CA,et al. 1999. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen induced arthritis in both injected anduninjected paws[J].Immunol, 162(6):3625~3632
William PA. 1997.The pathophysiology and treatment of rheumatoid arthritis[J]. Arthritis Rheum, 40(4):595~597
Wollheim FA,Telhag H,Henricesson A,et al. 1994. Prevention ofjoint destruction in antigen induced arthritis. Clin Immuno1Immunopatho1, 70:19~21
Wollheim FA,Telhag H,Henricesson A,et al. 1994.Prevention of joint destruction in antigen induced arthritis[J]. Clin Immuno1 Immunopatho1. 70:19~21
Wong S H, Lord JM. 2004. Factors underlying chronic inflammationin rheumatoid arthritis[J]. Arch Immunol Ther Exp, 52, 379~388
Wooley PH. 2004. Immunotherapy in collagen-induced arthritis: past,present,and future[J].Am J Med Sci. 327:217~226
Yamanishi Y, Boyle DL, Clark M, et al.,Expression and regulation of aggrecanase in arthritis:the role of TGF-beta.J Immunol. 2002. 168: 1405~1412
Yelin E, Wanke LA. 1999. An assessment of annual and long-term direct costs:the impact of poor functional decline[J].Arthritis Rheum. 42:1209~18
Yu WH, Yu S,Meng Q,et al. 2000,TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix.J Biol Chem. 275(40):31226~31232
Zhang G, Virikko KI,Myllyla R,et al. 2002.Surgical Procedure for intravascular delivery of plasmid DNA to organs.Methods Enzymol. 346:125~133
Zhang ZJ, Lee-Christopher SY, Lider O, et al. 1990.Suppression of adjuvantarthritis in Lewis rats by oral administration of typeⅡcollagen[J]. Immunol. 145:2489
Zini N; Lisignoli G; Solimando L. Maraldi NM. 2003. IL1-beta and TNF-alpha induce changes in the nuclear polyphosphoinositide signalling system in osteoblasts similar to that occurring in patients with rheumatoid arthritis: an immunochemical and immunocytochemical study [J]. Histochemistry and cell biology. 120: 243~250